Vaxcyte (PCVX) Competitors $35.28 -1.10 (-3.02%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$35.26 -0.02 (-0.04%) As of 07:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PCVX vs. ITCI, GMAB, RDY, MRNA, RGC, VTRS, ASND, QGEN, BPMC, and BBIOShould you be buying Vaxcyte stock or one of its competitors? The main competitors of Vaxcyte include Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Moderna (MRNA), Regencell Bioscience (RGC), Viatris (VTRS), Ascendis Pharma A/S (ASND), QIAGEN (QGEN), Blueprint Medicines (BPMC), and BridgeBio Pharma (BBIO). These companies are all part of the "pharmaceutical products" industry. Vaxcyte vs. Its Competitors Intra-Cellular Therapies Genmab A/S Dr. Reddy's Laboratories Moderna Regencell Bioscience Viatris Ascendis Pharma A/S QIAGEN Blueprint Medicines BridgeBio Pharma Vaxcyte (NASDAQ:PCVX) and Intra-Cellular Therapies (NASDAQ:ITCI) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership. Do insiders and institutionals hold more shares of PCVX or ITCI? 96.8% of Vaxcyte shares are owned by institutional investors. Comparatively, 92.3% of Intra-Cellular Therapies shares are owned by institutional investors. 3.1% of Vaxcyte shares are owned by insiders. Comparatively, 2.6% of Intra-Cellular Therapies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts recommend PCVX or ITCI? Vaxcyte presently has a consensus price target of $136.50, suggesting a potential upside of 286.90%. Intra-Cellular Therapies has a consensus price target of $109.70, suggesting a potential downside of 16.81%. Given Vaxcyte's stronger consensus rating and higher possible upside, equities research analysts plainly believe Vaxcyte is more favorable than Intra-Cellular Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vaxcyte 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.10Intra-Cellular Therapies 0 Sell rating(s) 10 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17 Is PCVX or ITCI more profitable? Vaxcyte has a net margin of 0.00% compared to Intra-Cellular Therapies' net margin of -14.07%. Intra-Cellular Therapies' return on equity of -9.93% beat Vaxcyte's return on equity.Company Net Margins Return on Equity Return on Assets VaxcyteN/A -17.12% -16.26% Intra-Cellular Therapies -14.07%-9.93%-8.38% Does the media prefer PCVX or ITCI? In the previous week, Vaxcyte had 3 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 4 mentions for Vaxcyte and 1 mentions for Intra-Cellular Therapies. Vaxcyte's average media sentiment score of 1.70 beat Intra-Cellular Therapies' score of 0.29 indicating that Vaxcyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxcyte 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Intra-Cellular Therapies 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better earnings & valuation, PCVX or ITCI? Intra-Cellular Therapies has higher revenue and earnings than Vaxcyte. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVaxcyteN/AN/A-$463.93M-$3.99-8.84Intra-Cellular Therapies$680.50M20.64-$139.67M-$0.73-180.64 Which has more risk & volatility, PCVX or ITCI? Vaxcyte has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. Comparatively, Intra-Cellular Therapies has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500. SummaryVaxcyte beats Intra-Cellular Therapies on 11 of the 16 factors compared between the two stocks. Get Vaxcyte News Delivered to You Automatically Sign up to receive the latest news and ratings for PCVX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PCVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PCVX vs. The Competition Export to ExcelMetricVaxcyteMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.69B$2.96B$5.61B$9.29BDividend YieldN/A2.43%4.23%4.03%P/E Ratio-8.8420.2228.5419.58Price / SalesN/A299.17429.2495.01Price / CashN/A43.1536.0257.93Price / Book1.337.568.145.54Net Income-$463.93M-$55.11M$3.24B$257.73M7 Day Performance-1.40%3.81%0.18%-0.08%1 Month Performance2.77%11.60%5.96%8.09%1 Year Performance-57.62%-2.11%26.24%13.02% Vaxcyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PCVXVaxcyte1.8152 of 5 stars$35.28-3.0%$136.50+286.9%-58.1%$4.69BN/A-8.84160Positive NewsITCIIntra-Cellular Therapies0.906 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S3.9125 of 5 stars$20.52+1.1%$37.60+83.2%-20.3%$13.16B$3.12B11.662,682Positive NewsAnalyst RevisionRDYDr. Reddy's Laboratories2.7713 of 5 stars$15.08flat$16.95+12.4%-9.5%$12.59B$3.81B22.8527,811Positive NewsMRNAModerna4.2776 of 5 stars$29.90-1.9%$46.61+55.9%-74.0%$11.56B$3.24B-3.425,800Analyst ForecastAnalyst RevisionGap UpRGCRegencell Bioscience0.3405 of 5 stars$18.43-19.8%N/AN/A$11.37BN/A0.0010Positive NewsGap DownVTRSViatris2.9047 of 5 stars$9.20-1.3%$10.40+13.0%-18.8%$10.80B$14.74B-2.9032,000News CoverageASNDAscendis Pharma A/S3.7113 of 5 stars$175.98+1.0%$220.67+25.4%+27.5%$10.76B$393.54M-28.021,017Positive NewsQGENQIAGEN3.682 of 5 stars$47.49-1.8%$49.40+4.0%+16.7%$10.56B$1.98B119.075,765Positive NewsBPMCBlueprint Medicines1.0974 of 5 stars$128.40+0.0%$128.06-0.3%+8.2%$8.29B$508.82M-51.98640Positive NewsBBIOBridgeBio Pharma4.6361 of 5 stars$43.50-1.1%$58.85+35.3%+68.7%$8.26B$221.90M-12.32400Analyst ForecastAnalyst Revision Related Companies and Tools Related Companies Intra-Cellular Therapies Competitors Genmab A/S Competitors Dr. Reddy's Laboratories Competitors Moderna Competitors Regencell Bioscience Competitors Viatris Competitors Ascendis Pharma A/S Competitors QIAGEN Competitors Blueprint Medicines Competitors BridgeBio Pharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PCVX) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxcyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxcyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PCVX Stock Alerts